EpEX, the soluble extracellular domain of EpCAM, resists cetuximab treatment of EGFR-high head and neck squamous cell carcinoma.

Koki Umemori,Kisho Ono,Takanori Eguchi,Hotaka Kawai,Tomoya Nakamura,Tatsuo Ogawa,Kunihiro Yoshida,Hideka Kanemoto,Kohei Sato,Kyoichi Obata,Shoji Ryumon,Hirokazu Yutori,Naoki Katase,Tatsuo Okui,Hitoshi Nagatsuka,Soichiro Ibaragi

Oral oncology（2023）

引用 2|浏览9

暂无评分

摘要

Soluble EpEX activates EGFR to increase Cmab resistance in HNSC cells. The EpEX-activated Cmab resistance in HNSC is potentially mediated by the EGFR-ERK signaling pathway and the EpCAM cleavage-induced nuclear translocation of EpICD. High expression and cleavage of EpCAM are potential biomarkers for predicting the clinical efficacy and resistance to Cmab.

查看译文

关键词

Cetuximab,epithelial cell adhesion molecule (EpCAM),EpEX,EpICD,epidermal growth factor receptor (EGFR),Drug resistance,Head and neck squamous cell carcinoma (HNSC)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要